Skip to Main content Skip to Navigation
Journal articles

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

Abstract : Aim: The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms. Materials & methods: We studied the effects of five polymorphisms in the VEGFA gene (-2549D/I, -1154G/A, -460T/C, +405G/C and +936C/T) on the outcome of 98 mCRC patients treated with FOLFIRI plus cetuximab. Results: Patients homozygous for the -2549D, -1154G and -460T alleles did exhibit higher response rates to treatment and longer progression-free survival compared with others. In addition, the DGTGC and IGCGC haplotypes were significantly associated with a lower risk of disease progression. Conclusion: These findings suggest that VEGFA genetic variations might influence response/resistance of FOLFIRI plus cetuximab treatment in mCRC patients.
Complete list of metadata

https://hal-univ-tours.archives-ouvertes.fr/hal-02381189
Contributor : Nicolas Azzopardi Connect in order to contact the contributor
Submitted on : Thursday, May 12, 2022 - 5:32:07 PM
Last modification on : Wednesday, May 25, 2022 - 3:45:24 AM

File

rollin2015.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Collections

Citation

Jérôme Rollin, Audrey Payancé, Valérie Gouilleux-Gruart, Michelle Boisdron-Celle, Nicolas Azzopardi, et al.. Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics, Future Medicine, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩. ⟨hal-02381189⟩

Share

Metrics

Record views

76

Files downloads

18